SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

Community sentiment remains deeply polarized as investors debate whether the asset represents a viable political statement or a speculative scam. Discussion is dominated by concerns over its significant decline from all-time highs, with many users warning of potential delistings while others continue to speculate on price volatility.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors debate the impact of broader market volatility, with community members actively discussing a potential breakout versus continued downside. Discussions center on the asset's long-term utility and historical halving cycles, contrasted with bearish sentiment surrounding its recent performance relative to other major cryptocurrencies.

Anthropic

Anthropic is currently dominating market discourse as it prepares for a highly anticipated IPO amidst intensified competition with OpenAI and recent regulatory scrutiny over the security of its latest AI models. Investors are closely tracking its strategic partnerships, multi-billion dollar infrastructure deals, and the rapid adoption of its Claude models as the company maneuvers through complex government relationships and rapid valuation growth.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is gaining traction as traders rotate into Japanese blockchain and IoT-focused projects, fueling renewed speculation about ecosystem expansion and potential institutional adoption. While community sentiment remains divided between skeptical bears citing long-term price action and bullish holders anticipating a breakout, activity is being supported by increasing trading volume and a technical setup that has caught the attention of speculative traders.

TOSHI

TOSHI is trending as the community expresses strong conviction in its pivot toward AI utility and revenue-sharing mechanisms, viewing current price levels as a prime accumulation zone. Investors are actively discussing the potential for a major breakout, citing the project's massive holder base and upcoming ecosystem developments as catalysts for a long-term recovery.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade is seeing significant volatility as investors weigh the company's AI-driven underwriting advancements and Tesla partnership against concerns about sustained profitability and high valuation multiples. The stock is currently a major talking point in community forums, with traders debating whether recent pullbacks represent an accumulation opportunity or a necessary correction following a sharp rally.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors monitor ongoing institutional accumulation, positive post-hoc trial analysis, and persistent rumors of a potential buyout, even as the stock experiences near-term volatility. The community remains sharply divided between bulls focused on the potential superiority of AXPAXLI over standard treatments and skeptics questioning the timing of the upcoming NDA submission and the intensity of competition.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased social media activity as community members debate its potential for long-term growth versus ongoing price stagnation, with some investors actively accumulating tokens during pullbacks. Sentiment remains polarized between those highlighting its technical benchmarks in quantum-resistant cryptography and others expressing frustration over historical price performance.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle Corp is trending as investors aggressively buy the stock amid a broader lithium market recovery, driven by tightening supply, record energy storage demand, and rising contract pricing. The community sentiment is largely bullish, with many long-term holders expressing relief as technical breakouts and upward analyst revisions validate their patience through previous cyclical lows.

Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA.

Tango Therapeutics Inc

Tango Therapeutics is trending as investors react to a significant clinical data update for its cancer drug combination, sparking high volatility, increased trading volume, and intense community debate over potential short-squeeze dynamics and future clinical milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Altimmune Worth Buying Ahead of 2026 Catalysts?

ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.

Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.

Madrigal Pharmaceuticals Q1 Earnings Call Highlights

Madrigal Pharmaceuticals (NASDAQ:MDGL) reported first-quarter 2026 net sales of $311.3 million as executives said demand for its MASH therapy Rezdiffra continued to build in a market they described as still early in development. On the company's earnings call, management highlighted patient growth...

Madrigal Pharmaceuticals (NASDAQ:MDGL) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $620.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Wednesday...

Madrigal (MDGL) Reports Q1 Loss, Beats Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of +9.97% and +3.38%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Madrigal Pharmaceuticals Posts Wider Loss In Q1

(RTTNews) - Wednesday, Madrigal Pharmaceuticals, Inc. (MDGL) announced its first-quarter financial results, reporting a net loss of $94.4 million, or $3.25 a share, compared to $73.2 million, or $2.61 a share, in the previous year...

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (NASDAQ: MDGL) for ARO-PNPLA3, Arrowheads clinical stage RNA...

Vanguard Group Inc. Trims Stake in Madrigal Pharmaceuticals, Inc. $MDGL

Vanguard Group Inc. reduced its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 0.2% in the fourth quarter, according to its most recent 13F filing with the...

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of therapeutics for metabolic dysfunction-associated steatohepatitis. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$2.49	--	--	N/A
Q1 '26	-$4.23	-$3.25	23.16%	BEAT
Q4 '25	-$1.00	-$2.57	-158.00%	MISSED
Q3 '25	-$2.29	-$5.08	-122.31%	MISSED
Q2 '25	-$3.55	-$1.90	46.54%	BEAT

MDGLMadrigal Pharmaceuticals Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest MDGL News